Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

PURPOSE: Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities. PATIENTS AND METHODS: We conducted a multicenter phase II trial of imatinib in metastatic mucosal, acral, or chronically sun-damaged (CSD) melanoma with KIT amplifications and/o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Hodi, F. Stephen, Corless, Christopher L., Giobbie-Hurder, Anita, Fletcher, Jonathan A., Zhu, Meijun, Marino-Enriquez, Adrian, Friedlander, Philip, Gonzalez, Rene, Weber, Jeffrey S., Gajewski, Thomas F., O'Day, Steven J., Kim, Kevin B., Lawrence, Donald, Flaherty, Keith T., Luke, Jason J., Collichio, Frances A., Ernstoff, Marc S., Heinrich, Michael C., Beadling, Carol, Zukotynski, Katherine A., Yap, Jeffrey T., Van den Abbeele, Annick D., Demetri, George D., Fisher, David E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2013
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878082/
https://ncbi.nlm.nih.gov/pubmed/23775962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.7836
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak